The effects of cosolutes on amyloid aggregation kinetics in vivo are critical and not fully understood. To explore the effects of cosolute additives, the in vitro behavior of destabilizing and stabilizing osmolytes with polymer cosolutes on the aggregation of a model amyloid, human insulin, is probed using experiments coupled with an amyloid aggregation reaction model. The destabilizing osmolyte, guanidine hydrochloride (GuHCl), induces biphasic behavior on the amyloid aggregation rate exhibited by an enhancement of the aggregation kinetics at low concentrations of GuHCl (<0.6 M) and a reduction in kinetics at higher GuHCl concentrations. Stabilizing osmolytes, glycerol, sorbitol and trimethylamine N-oxide, slow the rate of aggregation by reducing the rate of monomer unfolding. Polymer cosolutes, polyvinylpyrrolidone 3.5 kDa and 40 kDa, delay amyloid aggregation mainly through a decrease in the nucleation reaction. These results are in good agreement with the volume exclusion principle for polymer crowding and supports the need to include conformational rearrangement of monomers prior to nucleation. Using fluorescence correlation spectroscopy, we demonstrate that amyloid aggregation is nondiffusion limited, except during fibril accumulation in the presence of high concentrations of long chain polymers. Lastly, the neutral surface area of osmolytes correlates well with the time to initiate fibril formation, t(lag), which implicates an intrinsic osmolyte property underlying preferential interactions.